Page last updated: 2024-09-05

tak 779 and Atherogenesis

tak 779 has been researched along with Atherogenesis in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
de Vos, P; Fujiwara, H; Happé, H; Hauer, AD; Imanishi, T; Kuiper, J; van Berkel, TJ; van Wanrooij, EJ	1

Other Studies

1 other study(ies) available for tak 779 and Atherogenesis

Article	Year
HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arteriosclerosis, thrombosis, and vascular biology, 2005, Volume: 25, Issue:12 Topics: Amides; Animals; Anti-HIV Agents; Atherosclerosis; CCR5 Receptor Antagonists; Chemokine CCL4; Chemokine CCL5; Cholesterol; Female; Ligands; Lymphocyte Count; Macrophage Inflammatory Proteins; Mice; Mice, Mutant Strains; Quaternary Ammonium Compounds; Receptors, CCR5; Receptors, Chemokine; Receptors, CXCR3; Receptors, LDL; RNA, Messenger; Spleen; Th1 Cells	2005

Article

Year

HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice.

Arteriosclerosis, thrombosis, and vascular biology, 2005, Volume: 25, Issue:12

Topics: Amides; Animals; Anti-HIV Agents; Atherosclerosis; CCR5 Receptor Antagonists; Chemokine CCL4; Chemokine CCL5; Cholesterol; Female; Ligands; Lymphocyte Count; Macrophage Inflammatory Proteins; Mice; Mice, Mutant Strains; Quaternary Ammonium Compounds; Receptors, CCR5; Receptors, Chemokine; Receptors, CXCR3; Receptors, LDL; RNA, Messenger; Spleen; Th1 Cells

2005